On November 9, 2022 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the following upcoming investor conferences (Press release, Ultragenyx Pharmaceutical, NOV 9, 2022, View Source [SID1234623649]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel Healthcare Conference on Tuesday, November 15, 2022, at 1:50 PM EST in New York
Jefferies London Healthcare Conference on Thursday, November 17, 2022, at 10:25 AM GMT
The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

On November 9, 2022 BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") reported that it has completed a non-brokered private placement (the "Private Placement") consisting of 4,050,000 units ("Units") at a price of $0.10 per Unit for total gross proceeds of $405,000 (Press release, BioVaxys Technology, NOV 9, 2022, View Source [SID1234623648]). Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.20 for a period of 48 months.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company intends to use the net proceeds of the Private Placement for working capital purposes. The private placement is subject to the approval of the Canadian Securities Exchange.

The Company paid a finder’s fee of $18,400 in cash related to the financing.

In addition, the Company announces that further to its news release dated October 27, 2022, it has settled an aggregate of $150,000 in debt through the issuance of common shares issued at a deemed price of $0.20 per common share.

On November 9, 2022 Sysmex reported that Summary of Consolidated Financial Results [ IFRS ] for the First Six Months of the Fiscal Year Ending March 31, 202 (Press release, Sysmex, NOV 9, 2022, View Source [SID1234623647])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Results for the First Six Months of the Fiscal Year Ending March 31, 2023

(1) Operating results
(2) Financial condition

2. Dividend

3. Financial Forecast for the Year Ending March 31, 2023

4. Other Information
(1) Changes in significant consolidated subsidiaries (which resulted in changes in scope of consolidation): Yes Excluded: One company (Sysmex International Reagents Co., Ltd.)
(2) Changes in accounting policies and accounting estimates 1) Changes in accounting policies required by IFRS: No 2) Other changes in accounting policies:

No 3) Changes in accounting estimates:

No (3) Number of outstanding stock (common stock) 1) Number of outstanding stock at the end of each fiscal period (including treasury stock): 209,675,082 shares as of Sep. 30, 2022; 209,657,362 shares as of Mar. 31, 2022 2) Number of treasury stock at the end of each fiscal period: 447,308 shares as of Sep. 30, 2022; 447,255 shares as of Mar. 31, 2022 3) Average number of outstanding stock for each period (cumulative): 209,218,108 shares for the six months ended Sep. 30, 2022 209,014,581 shares for the six months ended Sep. 30, 2021

On November 9, 2022 Sysmex Corporation reported that actual financial results during the six months ended September 30, 2022, differed in some respects from the forecast announced on May 12, 2022 (Press release, Sysmex, NOV 9, 2022, View Source [SID1234623646]). In addition, Sysmex has revised its financial forecast for the full fiscal year ending March 31, 2023. These differences are described below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Differences between Actual and Forecast of Consolidated Financial Results for the Six Months Ended September 30, 2022 (April 1, 2022 to September 30, 2022)

2. Revised Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2023 (April 1, 2022 to March 31, 2023)

3. Reasons for the Differences and Revision

Consolidated net sales outpaced our previous forecast in the first six months of the fiscal year ending March 31, 2023. Although there was an influence of lockdowns and other factors in the China region, sales in the Americas, EMEA and Asia Pacific regions were solid, due to, but not limited to, foreign exchange rates that reflected greater-than-expected yen depreciation. On the profit front, despite the efforts to curtail SG&A expenses, operating profit, profit before tax and profit attributable to owners of the parent were lower than initially forecast because of the cost of sales which was higher than expected, due to increased raw materials prices and shipping costs by global inflation.

The results for the previous fiscal year, which are shown for reference, reflect the retroactive application of changes in the accounting treatment of cloud computing contracts made in the previous fiscal year. As for our forecast for the fiscal year ending March 31, 2023, although there are uncertainties such as geopolitical risks and risk of resurgence of COVID-19, we expect that sales will remain robust and greater-than-expected yen depreciation will continue.

For these reasons, we have revised upward our net sales forecast. Also we have revised upward our forecasts for operating profit, profit before tax and profit attributable to owners of the parent, as we continue to curtail cost of sales and SG&A expenses while the influence of global inflation is expected to remain.

We have revised our foreign exchange assumptions used for calculating financial forecasts from the third quarter onward from our initial assumptions of USD1.00 = JPY120, EUR1.00 = JPY130 and CNY1.00 = JPY18 to USD1.00 = JPY145, EUR1.00 = JPY142 and CNY1.00 = JPY20.

On November 9, 2022 Kureha Corporation reported that FY2022 Interim Report (Press release, Kureha Corporation, NOV 9, 2022, View Source [SID1234623645])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

FY2022 Overview Revenue and profit growth continues, absorbing impact of inflation and higher expenses ✓ Delivered half-year operating profit of ¥16.7bn, a 47% increase from a year ago, 29% above most recent forecast ✓ Full-year operating profit expected to reach ¥27.0bn (up 34% YoY; up 23% vs. initial forecast) 1Q-2Q FY22 business conditions

• Increased costs for coal (used at the Iwaki Factory) and basic chemicals (naphtha, benzene, VC monomers, etc.)
• Rising Inflation around the world, rapidly depreciating Japanese yen
• Continued market expansion for electric vehicles, partially offset by semiconductor shortages
• Strong agrochemicals demand propelled by increased farming activities and higher crop prices
• Limited impact of China’s lockdowns on our local PVDF manufacturing operations AM: Sales increased across all product groups, including advanced plastics, carbon products and other resin products; higher profit primarily driven by PVDF SC: Sales expansion for agrochemicals and industrial chemicals; higher profit led primarily by agrochemicals SP: Slower home products sales partially offset by the expansion of packaging materials CO: Fewer private construction projects; public construction remained on par with prior year OO: Fewer industrial waste treatment volumes, including low-level PCB wastesI.

FY2022 Half-Year (2Q) Results (April 1, 2022 through September 30, 2022)
Revenue increased with sales expansion of advanced plastics, particularly PVDF used as a binder material for lithium-ion batteries, and higher agrochemicals volumes resulting from front-loaded shipments
• Higher operating profit led by advanced plastics and agrochemicals
• Better-than-expected performances in advanced plastics, agrochemicals and home products